Press Releases

2022
2021
2020
All
Regulatory
Aug 12, 2022

Elicera Therapeutics announces participation in several industry and partnering conferences

Regulatory
Read more
Jun 2, 2022

Elicera Therapeutics receives 2.5 million Euros in EU funding to fully finance a clinical phase I/II-trial with its CAR T-cell therapy, ELC-301

Regulatory
Read more
Apr 27, 2022

Elicera Therapeutics successfully concludes preclinical proof-of-concept studies for oncolytic virus ELC-201 confirming the proposed mode-of-action

Regulatory
Read more
Apr 26, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2022

Regulatory
Read more
Apr 4, 2022

Elicera Therapeutics publishes scientific article in Nature Biomedical Engineering on the iTANK-platform and data indicating its universal compatibility with other CAR T-cell therapies

Regulatory
Read more
Feb 24, 2022

Elicera Therapeutics’ Chief Scientific Officer, Professor Magnus Essand, to present at SWECARNET’s Educational Day 2022

Regulatory
Read more
Feb 4, 2022

Elicera Therapeutics publishes annual report for 2021

Regulatory
Read more
Jan 25, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 December 2021

Regulatory
Read more
Jan 18, 2022

Elicera Therapeutics secures 5 million SEK in funding from Vinnova to develop an automated CAR T-cell manufacturing process

Regulatory
Read more
Jan 14, 2022

The Nomination Committee for Elicera Therapeutics proposes re-election of Board

Regulatory
Read more
Jan 5, 2022

Elicera Therapeutics strengthens IP protection for ELC-100 through acquisition of patent from Immunicum

Regulatory
Read more
Dec 15, 2021

Elicera Therapeutics enters into agreement with Baylor College of Medicine for contract manufacturing of next generation oncolytic virus, ELC-201

Regulatory
Read more
Nov 18, 2021

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 September 2021

Regulatory
Read more
Nov 9, 2021

Elicera Therapeutics enters agreement with BioNTech for contract manufacturing of viral vectors for CAR T-cell therapy

Regulatory
Read more
Nov 4, 2021

Nomination Committee for Elicera Therapeutics appointed

Regulatory
Read more
Oct 22, 2021

Elicera Therapeutics appoints professor Gunilla Enblad, Key Opinion Leader within the fields of CAR T-cells and B-cell lymphoma, as scientific advisor

Regulatory
Read more
Oct 20, 2021

Elicera Therapeutics presents preclinical proof-of-concept data for its iTANK-platform at the European Society of Cell & Gene Therapy Congress

Regulatory
Read more
Oct 5, 2021

Elicera Therapeutics announces participation in several industry and investor meetings in October and November

Regulatory
Read more
Sep 13, 2021

Elicera Therapeutics will present the iTANK platform orally at ESGCT Collaborative Virtual Congress and PEGS Europe

Regulatory
Read more
Aug 20, 2021

Interim Report Elicera Therapeutics AB January – June 2021

Regulatory
Read more
Jul 5, 2021

Elicera Therapeutics’ warrants (TO1) are listed on First North Growth Market

Regulatory
Read more
Jul 5, 2021

Elicera Therapeutics' board and management buy shares

Regulatory
Read more
Jun 24, 2021

Elicera Therapeutics receives ATMP-classification from EMA for oncolytic virus

Regulatory
Read more
Jun 10, 2021

Elicera Therapeutics has been approved for listing on Nasdaq First North Growth Market

Regulatory
Read more
Jun 9, 2021

Elicera Therapeutics' new issue heavily oversubscribed

Regulatory
Read more
Jun 4, 2021

Elicera Therapeutics’ last day to subscribe ahead of the listing at Nasdaq First North Growth Market

Regulatory
Read more
May 24, 2021

Elicera Therapeutics’ first day to subscribe ahead of the listing at Nasdaq First North Growth Market

Regulatory
Read more
Apr 27, 2021

Elicera Therapeutics files a patent application for the development of the next generation oncolytic viruses

Regulatory
Read more
Apr 15, 2021

Biostock writes about Elicera and CAR T-cells

Regulatory
Read more
Mar 22, 2021

Elicera announces appointment of ATMP specialist Karin Hoogendoorn to the Board

Regulatory
Read more
Jan 11, 2021

Elicera Therapeutics recruits CFO

Regulatory
Read more
Jan 8, 2021

Elicera Therapeutics invitation to company presentation (in Swedish)

Regulatory
Read more
Oct 5, 2020

Elicera Therapeutics completes oversubscribed share issue and launches unique immuno-oncology company with focus on CAR T-cells and oncolytic viruses

Regulatory
Read more
Apr 23, 2020

Elicera Therapeutics announces the next safety update in the phase I/II study with ELC-100

Regulatory
Read more
Jun 2, 2022

Elicera Therapeutics receives 2.5 million Euros in EU funding to fully finance a clinical phase I/II-trial with its CAR T-cell therapy, ELC-301

Regulatory
Read more
Apr 26, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2022

Regulatory
Read more
Apr 4, 2022

Elicera Therapeutics publishes scientific article in Nature Biomedical Engineering on the iTANK-platform and data indicating its universal compatibility with other CAR T-cell therapies

Regulatory
Read more
Feb 4, 2022

Elicera Therapeutics publishes annual report for 2021

Regulatory
Read more
Jan 25, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 December 2021

Regulatory
Read more
Jan 14, 2022

The Nomination Committee for Elicera Therapeutics proposes re-election of Board

Regulatory
Read more
Nov 18, 2021

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 September 2021

Regulatory
Read more
Nov 4, 2021

Nomination Committee for Elicera Therapeutics appointed

Regulatory
Read more
Oct 20, 2021

Elicera Therapeutics presents preclinical proof-of-concept data for its iTANK-platform at the European Society of Cell & Gene Therapy Congress

Regulatory
Read more
All
Regulatory
Aug 12, 2022

Elicera Therapeutics announces participation in several industry and partnering conferences

Regulatory
Read more
Jun 2, 2022

Elicera Therapeutics receives 2.5 million Euros in EU funding to fully finance a clinical phase I/II-trial with its CAR T-cell therapy, ELC-301

Regulatory
Read more
Apr 27, 2022

Elicera Therapeutics successfully concludes preclinical proof-of-concept studies for oncolytic virus ELC-201 confirming the proposed mode-of-action

Regulatory
Read more
Apr 26, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2022

Regulatory
Read more
Apr 4, 2022

Elicera Therapeutics publishes scientific article in Nature Biomedical Engineering on the iTANK-platform and data indicating its universal compatibility with other CAR T-cell therapies

Regulatory
Read more
Feb 24, 2022

Elicera Therapeutics’ Chief Scientific Officer, Professor Magnus Essand, to present at SWECARNET’s Educational Day 2022

Regulatory
Read more
Feb 4, 2022

Elicera Therapeutics publishes annual report for 2021

Regulatory
Read more
Jan 25, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 December 2021

Regulatory
Read more
Jan 18, 2022

Elicera Therapeutics secures 5 million SEK in funding from Vinnova to develop an automated CAR T-cell manufacturing process

Regulatory
Read more
Jan 14, 2022

The Nomination Committee for Elicera Therapeutics proposes re-election of Board

Regulatory
Read more
Jan 5, 2022

Elicera Therapeutics strengthens IP protection for ELC-100 through acquisition of patent from Immunicum

Regulatory
Read more
Dec 15, 2021

Elicera Therapeutics enters into agreement with Baylor College of Medicine for contract manufacturing of next generation oncolytic virus, ELC-201

Regulatory
Read more
Nov 18, 2021

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 September 2021

Regulatory
Read more
Nov 9, 2021

Elicera Therapeutics enters agreement with BioNTech for contract manufacturing of viral vectors for CAR T-cell therapy

Regulatory
Read more
Nov 4, 2021

Nomination Committee for Elicera Therapeutics appointed

Regulatory
Read more
Oct 22, 2021

Elicera Therapeutics appoints professor Gunilla Enblad, Key Opinion Leader within the fields of CAR T-cells and B-cell lymphoma, as scientific advisor

Regulatory
Read more
Oct 20, 2021

Elicera Therapeutics presents preclinical proof-of-concept data for its iTANK-platform at the European Society of Cell & Gene Therapy Congress

Regulatory
Read more
Oct 5, 2021

Elicera Therapeutics announces participation in several industry and investor meetings in October and November

Regulatory
Read more
Sep 13, 2021

Elicera Therapeutics will present the iTANK platform orally at ESGCT Collaborative Virtual Congress and PEGS Europe

Regulatory
Read more
Aug 20, 2021

Interim Report Elicera Therapeutics AB January – June 2021

Regulatory
Read more
Jul 5, 2021

Elicera Therapeutics’ warrants (TO1) are listed on First North Growth Market

Regulatory
Read more
Jul 5, 2021

Elicera Therapeutics' board and management buy shares

Regulatory
Read more
Jun 24, 2021

Elicera Therapeutics receives ATMP-classification from EMA for oncolytic virus

Regulatory
Read more
Jun 10, 2021

Elicera Therapeutics has been approved for listing on Nasdaq First North Growth Market

Regulatory
Read more
Jun 9, 2021

Elicera Therapeutics' new issue heavily oversubscribed

Regulatory
Read more
Jun 4, 2021

Elicera Therapeutics’ last day to subscribe ahead of the listing at Nasdaq First North Growth Market

Regulatory
Read more
May 24, 2021

Elicera Therapeutics’ first day to subscribe ahead of the listing at Nasdaq First North Growth Market

Regulatory
Read more
Apr 27, 2021

Elicera Therapeutics files a patent application for the development of the next generation oncolytic viruses

Regulatory
Read more
Apr 15, 2021

Biostock writes about Elicera and CAR T-cells

Regulatory
Read more
Mar 22, 2021

Elicera announces appointment of ATMP specialist Karin Hoogendoorn to the Board

Regulatory
Read more
Jan 11, 2021

Elicera Therapeutics recruits CFO

Regulatory
Read more
Jan 8, 2021

Elicera Therapeutics invitation to company presentation (in Swedish)

Regulatory
Read more
Oct 5, 2020

Elicera Therapeutics completes oversubscribed share issue and launches unique immuno-oncology company with focus on CAR T-cells and oncolytic viruses

Regulatory
Read more
Apr 23, 2020

Elicera Therapeutics announces the next safety update in the phase I/II study with ELC-100

Regulatory
Read more
Jun 2, 2022

Elicera Therapeutics receives 2.5 million Euros in EU funding to fully finance a clinical phase I/II-trial with its CAR T-cell therapy, ELC-301

Regulatory
Read more
Apr 26, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2022

Regulatory
Read more
Apr 4, 2022

Elicera Therapeutics publishes scientific article in Nature Biomedical Engineering on the iTANK-platform and data indicating its universal compatibility with other CAR T-cell therapies

Regulatory
Read more
Feb 4, 2022

Elicera Therapeutics publishes annual report for 2021

Regulatory
Read more
Jan 25, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 December 2021

Regulatory
Read more
Jan 14, 2022

The Nomination Committee for Elicera Therapeutics proposes re-election of Board

Regulatory
Read more
Nov 18, 2021

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 September 2021

Regulatory
Read more
Nov 4, 2021

Nomination Committee for Elicera Therapeutics appointed

Regulatory
Read more
Oct 20, 2021

Elicera Therapeutics presents preclinical proof-of-concept data for its iTANK-platform at the European Society of Cell & Gene Therapy Congress

Regulatory
Read more
All
Regulatory
Aug 12, 2022

Elicera Therapeutics announces participation in several industry and partnering conferences

Regulatory
Read more
Jun 2, 2022

Elicera Therapeutics receives 2.5 million Euros in EU funding to fully finance a clinical phase I/II-trial with its CAR T-cell therapy, ELC-301

Regulatory
Read more
Apr 27, 2022

Elicera Therapeutics successfully concludes preclinical proof-of-concept studies for oncolytic virus ELC-201 confirming the proposed mode-of-action

Regulatory
Read more
Apr 26, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2022

Regulatory
Read more
Apr 4, 2022

Elicera Therapeutics publishes scientific article in Nature Biomedical Engineering on the iTANK-platform and data indicating its universal compatibility with other CAR T-cell therapies

Regulatory
Read more
Feb 24, 2022

Elicera Therapeutics’ Chief Scientific Officer, Professor Magnus Essand, to present at SWECARNET’s Educational Day 2022

Regulatory
Read more
Feb 4, 2022

Elicera Therapeutics publishes annual report for 2021

Regulatory
Read more
Jan 25, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 December 2021

Regulatory
Read more
Jan 18, 2022

Elicera Therapeutics secures 5 million SEK in funding from Vinnova to develop an automated CAR T-cell manufacturing process

Regulatory
Read more
Jan 14, 2022

The Nomination Committee for Elicera Therapeutics proposes re-election of Board

Regulatory
Read more
Jan 5, 2022

Elicera Therapeutics strengthens IP protection for ELC-100 through acquisition of patent from Immunicum

Regulatory
Read more
Dec 15, 2021

Elicera Therapeutics enters into agreement with Baylor College of Medicine for contract manufacturing of next generation oncolytic virus, ELC-201

Regulatory
Read more
Nov 18, 2021

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 September 2021

Regulatory
Read more
Nov 9, 2021

Elicera Therapeutics enters agreement with BioNTech for contract manufacturing of viral vectors for CAR T-cell therapy

Regulatory
Read more
Nov 4, 2021

Nomination Committee for Elicera Therapeutics appointed

Regulatory
Read more
Oct 22, 2021

Elicera Therapeutics appoints professor Gunilla Enblad, Key Opinion Leader within the fields of CAR T-cells and B-cell lymphoma, as scientific advisor

Regulatory
Read more
Oct 20, 2021

Elicera Therapeutics presents preclinical proof-of-concept data for its iTANK-platform at the European Society of Cell & Gene Therapy Congress

Regulatory
Read more
Oct 5, 2021

Elicera Therapeutics announces participation in several industry and investor meetings in October and November

Regulatory
Read more
Sep 13, 2021

Elicera Therapeutics will present the iTANK platform orally at ESGCT Collaborative Virtual Congress and PEGS Europe

Regulatory
Read more
Aug 20, 2021

Interim Report Elicera Therapeutics AB January – June 2021

Regulatory
Read more
Jul 5, 2021

Elicera Therapeutics’ warrants (TO1) are listed on First North Growth Market

Regulatory
Read more
Jul 5, 2021

Elicera Therapeutics' board and management buy shares

Regulatory
Read more
Jun 24, 2021

Elicera Therapeutics receives ATMP-classification from EMA for oncolytic virus

Regulatory
Read more
Jun 10, 2021

Elicera Therapeutics has been approved for listing on Nasdaq First North Growth Market

Regulatory
Read more
Jun 9, 2021

Elicera Therapeutics' new issue heavily oversubscribed

Regulatory
Read more
Jun 4, 2021

Elicera Therapeutics’ last day to subscribe ahead of the listing at Nasdaq First North Growth Market

Regulatory
Read more
May 24, 2021

Elicera Therapeutics’ first day to subscribe ahead of the listing at Nasdaq First North Growth Market

Regulatory
Read more
Apr 27, 2021

Elicera Therapeutics files a patent application for the development of the next generation oncolytic viruses

Regulatory
Read more
Apr 15, 2021

Biostock writes about Elicera and CAR T-cells

Regulatory
Read more
Mar 22, 2021

Elicera announces appointment of ATMP specialist Karin Hoogendoorn to the Board

Regulatory
Read more
Jan 11, 2021

Elicera Therapeutics recruits CFO

Regulatory
Read more
Jan 8, 2021

Elicera Therapeutics invitation to company presentation (in Swedish)

Regulatory
Read more
Oct 5, 2020

Elicera Therapeutics completes oversubscribed share issue and launches unique immuno-oncology company with focus on CAR T-cells and oncolytic viruses

Regulatory
Read more
Apr 23, 2020

Elicera Therapeutics announces the next safety update in the phase I/II study with ELC-100

Regulatory
Read more
Jun 2, 2022

Elicera Therapeutics receives 2.5 million Euros in EU funding to fully finance a clinical phase I/II-trial with its CAR T-cell therapy, ELC-301

Regulatory
Read more
Apr 26, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2022

Regulatory
Read more
Apr 4, 2022

Elicera Therapeutics publishes scientific article in Nature Biomedical Engineering on the iTANK-platform and data indicating its universal compatibility with other CAR T-cell therapies

Regulatory
Read more
Feb 4, 2022

Elicera Therapeutics publishes annual report for 2021

Regulatory
Read more
Jan 25, 2022

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 December 2021

Regulatory
Read more
Jan 14, 2022

The Nomination Committee for Elicera Therapeutics proposes re-election of Board

Regulatory
Read more
Nov 18, 2021

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 September 2021

Regulatory
Read more
Nov 4, 2021

Nomination Committee for Elicera Therapeutics appointed

Regulatory
Read more
Oct 20, 2021

Elicera Therapeutics presents preclinical proof-of-concept data for its iTANK-platform at the European Society of Cell & Gene Therapy Congress

Regulatory
Read more

Sign up for Press Releases

By filling out the form you are approving that Elicera stores your information. Read more about our integrity policy here.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Shaking hands in agreement
Elicera Therapeutics AB is a clinical stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments.

Org.nr: 556966-4955
Elicera Therapeutics AB (publ)
World Trade Center Göteborg
Mässans gata 10, floor 7
412 51, Göteborg
info@elicera.com
+46 (0)70-331 90 51‬
Integrity Policy
By continuing to browse this website you agree to cookies being stored on your device in order to improve the experience and analyze how it is being used. Read more in our Integrity policy.